METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS

Abstract

Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.

We claim: 
     
         1 . A pharmaceutical preparation for use in prophylaxis and/or therapy of ErbB2-positive cancer comprising an isolated or recombinantly produced peptidase D (PEPD) and at least one pharmaceutically acceptable carrier. 
     
     
         2 . The pharmaceutical preparation of  claim 1 , wherein the PEPD is a component of a fusion protein. 
     
     
         3 . The pharmaceutical preparation of  claim 2 , wherein the fusion protein comprises the PEPD and a polyhistidine tag. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the PEPD is coupled to a chemotherapeutic agent. 
     
     
         5 . The pharmaceutical preparation of  claim 2 , wherein the fusion protein comprises the PEPD and an Fc region of an immunoglobulin. 
     
     
         6 . The pharmaceutical preparation of  claim 1 , wherein the PEPD has less dipeptide hydrolysis activity as compared to a PEPD comprising the sequence of SEQ ID NO:1. 
     
     
         7 . The pharmaceutical preparation of  claim 6 , wherein the PEPD comprises a mutation of glycine at position 278 of SEQ ID NO:1. 
     
     
         8 . The pharmaceutical preparation of  claim 1 , further comprising a coagulation inhibitor. 
     
     
         9 . A product for use in prophylaxis and/or therapy of ErbB2-positive cancer comprising at least one sealed container which contains a pharmaceutical preparation comprising peptidase D (PEPD), wherein the product comprises printed material which provides an indication that the pharmaceutical preparation is for use in prophylaxis and/or therapy of ErbB2-positive cancer in an individual. 
     
     
         10 . The product of  claim 9 , wherein the PEPD has less dipeptide hydrolysis activity as compared to a PEPD comprising the sequence of SEQ ID NO:1. 
     
     
         11 . The product of  claim 9 , further comprising a coagulation inhibitor, and/or an indication that the pharmaceutical preparation is for use with a coagulation inhibitor.